Regeneration After Radiation- and Immune-Mediated Tissue Injury Is Not Enhanced by Type III Interferon Signaling.
Animals
Hematopoietic Stem Cell Transplantation
/ adverse effects
Interferons
/ metabolism
Intestinal Mucosa
/ pathology
Intestines
/ cytology
Mice
Regeneration
/ radiation effects
Signal Transduction
/ radiation effects
Thymus Gland
/ injuries
Whole-Body Irradiation
/ adverse effects
Interferon Lambda
Journal
International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616
Informations de publication
Date de publication:
15 03 2019
15 03 2019
Historique:
received:
18
07
2018
revised:
26
10
2018
accepted:
19
11
2018
pubmed:
7
12
2018
medline:
7
9
2019
entrez:
4
12
2018
Statut:
ppublish
Résumé
Type I interferon (IFN-I) and interleukin (IL)-22 modulate regeneration of the thymus and intestinal epithelial cells (IECs) after cytotoxic stress such as irradiation. Radiation-induced damage to thymic tissues and IECs is a crucial aspect during the pathogenesis of inadequate immune reconstitution and acute graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with myeloablative total body irradiation (TBI), respectively. IL-22 and IFN-I reduce the severity of acute GVHD after allo-HSCT with myeloablative TBI. However, the role of biologically related type III interferon (IFN-III), also known as interferon lambda (IFN-λ) or IL-28, in this context is unclear. We therefore studied the role of the IFN-III pathway in thymic regeneration and GVHD after TBI and allo-HSCT. Cohoused wild-type (WT) and IFN-III receptor-deficient (IL-28 receptor alpha subunit-deficient/IL-28Ra The course and severity of GVHD after myeloablative TBI and allo-HSCT in IL-28Ra We analyzed the role of IFN-III signaling during radiation-mediated acute tissue injury. Despite molecular and biologic homologies with IFN-I and IL-22, IFN-III signaling did not improve thymus regeneration after radiation or the course of GVHD after myeloablative TBI and allo-HSCT.
Identifiants
pubmed: 30503785
pii: S0360-3016(18)34024-0
doi: 10.1016/j.ijrobp.2018.11.038
pii:
doi:
Substances chimiques
Interferons
9008-11-1
Interferon Lambda
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
970-976Informations de copyright
Copyright © 2018 Elsevier Inc. All rights reserved.